Connect with us

Technology

Clinical Trial Management System (CTMS) Market size is set to grow by USD 1.86 billion from 2024-2028, Increasing healthcare expenditure to boost the market growth, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global clinical trial management system (CTMS) market size is estimated to grow by USD 1.86 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 14.27% during the forecast period. Increasing healthcare expenditure is driving market growth, with a trend towards increasing outsourcing of clinical trial process. However, rising cost of clinical trials poses a challenge. Key market players include Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies – Click for the snapshot of this report

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

Deployment (On-premise and Cloud), End-user (Pharmaceutical and biotechnology companies, CROs, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd.

 

Key Market Trends Fueling Growth

In the pharmaceutical industry, the shift towards outsourcing drug discovery processes to subcontract laboratories has been a significant trend since 2011. This transformation has enabled small companies to focus on manufacturing and marketing activities while outsourcing research and testing to external resources. The increasing popularity of this approach is due to the substantial cost savings it offers, as companies can outsource these functions for a fraction of the cost of building and maintaining their own research facilities. This outsourcing trend is particularly prevalent in countries like the US, the UK, Germany, and Japan, which have been outsourcing drug discovery to emerging economies such as India and Brazil. The high volume of data generated during the drug discovery process necessitates the use of Clinical Trial Management Systems (CTMS) to manage and analyze this data effectively. The growing number of tests carried out in subcontract laboratories has led to a corresponding increase in demand for CTMS solutions. CTMS plays a crucial role in streamlining the clinical trial process, ensuring compliance with regulatory requirements, and facilitating data management and analysis. As the outsourcing trend continues, the demand for CTMS is expected to grow, providing opportunities for market expansion. 

The Clinical Trial Management System (CTMS) market is experiencing significant trends that are transforming the clinical trial landscape. Robust reporting and centralizing recruitment are key priorities for multinational companies and local CROs. ERegulatory, eSOURCE, accounting, and aggregate reporting provide network-wide visibility and oversight. Digitalization, personalized medicine, outsourcing, and externalization are driving growth in the market. Robust reporting, decentralized trial models, and evidence-based facilities are essential for regulatory compliance. ERegulatory, ERT, and Bioclinica are leading providers in Healthcare IT. Cloud-based CTMS, telemedicine solutions, and decentralized clinical trials are crucial in the current COVID-19 era. Costs, system security, backups, upgrades, and uptime consistency are critical considerations for CTM systems. AI and machine learning are enhancing trial efficiency and reducing costs. Vaccines and CTM systems are essential in the fight against COVID-19. The market is expected to continue growing, with investment in digitalization and regulatory policies being key drivers. 

Discover 360° analysis of this market. For complete information, schedule your consultation- Book Here!

Market Challenges

Clinical trials are a crucial part of bringing new drugs to market, but their rising costs are a significant concern for the pharmaceutical industry. One major challenge is patient enrollment and retention, which can prolong the trial duration and increase expenses. According to various studies, the average cost per patient in the US for clinical trials is approximately USD41,117, with phase 3 trials being the most expensive, costing around USD20 million. Another factor contributing to the rising costs is the need for extensive clinical data collection due to new regulations. This can make trials complex and expensive, especially for drugs targeting chronic diseases. The longer a trial lasts, the more it costs, making clinical trial management systems essential to streamline the process. However, some clinical research associates may prefer manual work to cut costs, hindering the growth of the market. To address this issue, increasing patient awareness is the most feasible solution. By educating patients about the importance and benefits of clinical trials, the number of willing participants is likely to rise, reducing the overall cost and duration of trials. Pharmaceutical companies should focus on patient education rather than persuasion to ensure a successful clinical trial process.In the dynamic healthcare IT landscape, Clinical Trial Management Systems (CTMS) have become essential tools for managing complex clinical trials. However, implementing CTMS comes with challenges. Decentralized trials and the rise of vaccines require cloud-based CTMS for flexibility. Telemedicine solutions and COVID-NMA necessitate robust system security, backups, and upgrades. Centralization of data, growth, and AI/machine learning algorithms demand uptime consistency and automation. Clinical trial managers need access to data on devices like mobile workstations, laptops, and tablets via online dashboards. Trial planning, monitoring activities, regulatory procedures, supplies, finance, and subscription-based software upgrades require scalability. Add-ons, regulatory norms, document management processes, data quality, participant safety, and adherence to regulatory procedures are key considerations. Solutions like Clinion offer IWRS/RTSM, EDC, eCOA, accruals, deviations, and scalability to address these challenges.

For more insights on driver and challenges – Download a Sample Report

Segment Overview 

This clinical trial management system (ctms) market report extensively covers market segmentation by

Deployment 1.1 On-premise1.2 CloudEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 CROs2.3 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 On-premise- The Clinical Trial Management System (CTMS) market primarily consists of on-premises and cloud-based deployment models. On-premises CTMS offers enhanced data security and control, making it a preferred choice for large firms. However, the significant investment required for infrastructure and maintenance poses a challenge for smaller organizations. Conversely, cloud-based CTMS offers cost-effectiveness and ease of use. Major on-premises CTMS vendors include Siebel and IMPACT. Despite the high cost, large firms continue to prefer on-premises CTMS due to the perceived level of data security. This segment’s growth in the global CTMS market is anticipated to be driven by these factors during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 – 2022) – Download a Sample Report

Research Analysis

The Clinical Trial Management System (CTMS) market is a significant segment of Healthcare IT, facilitating the planning, execution, and management of clinical trials. With the increasing focus on decentralized clinical trials and the development of vaccines, CTMS solutions have gained prominence. Cloud-based CTMS is a popular choice due to its accessibility, scalability, and cost-effectiveness. Telemedicine solutions and IWRS/RTSM integrate seamlessly with CTMS, enhancing trial efficiency. EDC, eCOA, accruals, deviations, and robust reporting are essential features. Outsourcing and externalization to multinational companies and local CROs are common practices. Regulatory policies necessitate investment in CTMS solutions for ensuring compliance. Clario and other advanced systems offer features like ERT, making trial management more streamlined.

Market Research Overview

The Clinical Trial Management System (CTMS) market in Healthcare IT is experiencing significant growth due to the increasing adoption of decentralized clinical trials, particularly in the development of vaccines. Cloud-based CTMS solutions are gaining popularity for their accessibility and cost-effectiveness. Telemedicine solutions and AI-driven technologies, including machine learning algorithms and automation, are being integrated into CTMS to improve efficiency and data quality. Costs, system security, backups, and upgrades are key considerations for CTMS implementation. Uptime consistency, centralization of data, and regulatory norms are crucial for ensuring trial integrity and participant safety. Clinical trial managers require access to real-time data from devices such as mobile workstations, laptops, tablets, and online dashboards for effective trial planning, monitoring activities, and regulatory procedures. CTMS systems include modules for supplies, finance, and accounting on a subscription basis, with software upgrades and add-ons available for customization. Digitalization of clinical trials through eRegulatory, eSOURCE, IWRS/RTSM, EDC, eCOA, accruals, deviations, and scalable, robust reporting is driving growth in the market. Centralizing recruitment and network-wide visibility are also important for oversight and personalized medicine initiatives. Outsourcing and externalization to local CROs and multinational companies are common practices in the industry. Clario and other trial models are embracing decentralized approaches and evidence-based facilities to streamline regulatory policies and investment in the sector.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

DeploymentOn-premiseCloudEnd-userPharmaceutical And Biotechnology CompaniesCROsOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-trial-management-system-ctms-market-size-is-set-to-grow-by-usd-1-86-billion-from-2024-2028–increasing-healthcare-expenditure-to-boost-the-market-growth-technavio-302208770.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Portland Public Library Delivers Almost 50% Increase In User Engagement with New Web Redesign

Published

on

By

MIAMI, April 21, 2026 /PRNewswire/ — Digital Silk, an award-winning agency focused on creating brand strategies, custom websites, and digital marketing campaigns, announces the launch of a redesigned website for Portland Public Library, a public institution serving the education, community services, and nonprofit sector. The project focuses on improving user experience, content discoverability, and engagement while introducing a scalable CMS to support ongoing updates. The new platform is now live at https://www.portlandlibrary.org/.

The redesigned website reflects a strategic effort to better serve a diverse audience by improving navigation, enhancing accessibility, and creating clearer pathways to programs, events, and resources.

Improving Engagement Through User-Centric Design

Portland Public Library required a modern digital platform to address challenges related to fragmented navigation, limited engagement pathways, and difficulty in accessing content. The previous website structure made it harder for users to find relevant information efficiently.

Digital Silk addressed these challenges through a full website redesign supported by user-centric information architecture and optimized user journeys. The updated experience prioritizes clarity, accessibility, and ease of navigation across a wide range of services and resources.

“Organizations like public libraries are increasingly relying on their digital platforms to serve as primary engagement hubs, making usability and content clarity more important than ever,” said Ana Margarida Meira, VP, Client Partner.

Measurable Improvements in User Engagement

Following the launch, Portland Public Library recorded measurable improvements in engagement metrics when comparing Feb 17 to Mar 23, 2026, against the previous period.

Key outcomes include:

+47.82% increase in average engagement time per active user+4.5% increase in engaged sessions per active user+18.38% increase in average engagement time per session

These improvements may indicate stronger interaction with site content and increased user engagement across programs and services.

Key Deliverables Supporting Accessibility and Scalability

The project combined design, UX strategy, and technical development to support both immediate engagement improvements and long-term flexibility.

Core deliverables included:

Full website redesign and developmentUser-centric information architectureEngagement-focused UX design and user journey optimizationInclusive design enhancementsScalable CMS with modular content componentsPerformance optimization and QA testing

The implementation enables the library’s internal team to manage content more efficiently while supporting dynamic updates for seasonal programming and community initiatives.

Supporting a Shift Toward Inclusive Digital Experiences

The project reflects a broader trend among public institutions and content-heavy organizations to prioritize inclusive design, improved content discoverability, and scalable content management systems. Increasingly, organizations are focusing on engagement metrics as a measure of digital effectiveness.

“A well-structured, user-centric website can significantly increase engagement by making it easier for diverse audiences to find, explore, and interact with valuable resources and services,” said Ana Margarida Meira, VP, Client Partner.

Building a Foundation for Ongoing Community Engagement

The redesigned platform provides Portland Public Library with a flexible and scalable foundation to support future growth. By improving accessibility and navigation, the website is positioned to better connect users with educational programs, community services, and digital resources.

More information about Digital Silk’s web development capabilities is available at https://www.digitalsilk.com/ and organizations can request a quote here

About Digital Silk

Digital Silk is an award-winning Miami Web Development Agency focused on growing brands online. With a team of seasoned experts, Digital Silk creates digital experiences through strategic branding, custom web design, and digital marketing services to help improve visibility and support engagement.

Media Contact

Jessica Erasmus
Marketing Director & PR Manager
Tel: (800) 206-9413
Email: jessica@digitalsilk.com

View original content:https://www.prnewswire.com/news-releases/portland-public-library-delivers-almost-50-increase-in-user-engagement-with-new-web-redesign-302747609.html

SOURCE Digital Silk

Continue Reading

Technology

LUMA Vision to Showcase VERAFEYE 4D Imaging Platform at HRS 2026, Signaling a New Foundation for EP Guidance

Published

on

By

DUBLIN, April 21, 2026 /PRNewswire/ — LUMA Vision, a leader in real-time 4D cardiac imaging and navigation, today announced its participation in the Heart Rhythm Society Annual Meeting (HRS 2026) in Chicago, where the company will showcase its VERAFEYE™ Visualization and Guidance Platform and highlight new clinical progress through physician-led presentations and scientific sessions.

At HRS 2026, LUMA Vision will demonstrate how VERAFEYE enables direct, real-time visualization of cardiac anatomy, catheters, and therapy delivery—a step-change from conventional imaging and mapping approaches. By combining live 2D and 4D intra-procedural imaging with precise digital anatomical models, the platform delivers CT-quality visualization in seconds, supporting faster, more intuitive, and more precise procedures.

VERAEYE is redefining EP Guidance — from tools to platform, VERAFEYE is designed to eliminate the fragmentation of current EP workflows by enabling physicians to see and guide therapy in real time, rather than relying on the traditional three separate systems of point-by-point mapping, ICE and fluoroscopy. Early clinical experience demonstrates the platform’s ability to:

Enable efficient single-operator workflowsSupport multiple ablation technologiesEliminate the use of fluoroscopyIntroduce a true two-catheter procedure

LUMA Vision will be featured across multiple sessions:

Wednesday, April 22 | 3:00 PM Embassy Suites by Hilton Chicago
Dr. Shephal Doshi will present at the Stanford Biodesign New Arrhythmia Technologies Retreat, highlighting the role of real-time 4D imaging in advancing EP innovation.

Thursday, April 23 | 5:00 PM McCormick Place Convention Center • Room S406AB
Dr. Vivek Reddy will present “AF Ablation with a Large-Focal PFA Catheter & Integrated Guidance” at the 3rd Annual PFA LIVE Case Summit, featuring the VERAFEYE™ System in collaboration with CardioFocus.

Saturday, April 25 | Time 12:00 to 2:00 PM Abstract Pavilion, McCormick Place (Exhibit Hall)
Dr. Toni Breskovic will present new clinical data demonstrating real-world workflow validation and procedural impact.

“This is a defining moment not only for LUMA Vision, but for the future architecture of cardiac procedures. VERAFEYE is a globally unique, AI–powered system that sits at the intersection of electrophysiology, left atrial appendage closure, and structural heart interventions, designed as a unified operating layer rather than a standalone procedural tool,” said Fionn Lahart, CEO of LUMA Vision. “What we are introducing with VERAFEYE is a unified, real–time view of the heart that has the potential to become the foundation for how cardiac procedures are performed.  As the field advances toward next–generation ablation technologies, guidance will no longer be an accessory. It will be the AI–enabled decision–making platform on which everything else is built.”

Driven by advanced AI algorithms, VERAFEYE interprets cardiac anatomy in real time, creating a single anatomical and guidance framework that spans multiple procedures. This intelligent foundation establishes a common procedural language through which therapies can enable greater precision, more efficient workflows, and tighter integration across the cardiac ecosystem.

Throughout the week, attendees are invited to visit Booth #2415 to meet the clinical team and experience how VERAFEYE delivers CT-quality digital anatomy in seconds, enabling a new level of precision and control in EP procedures. As EP continues to evolve toward energy-agnostic, platform-driven workflows, VERAFEYE is positioned to serve as a foundational imaging layer integrating across mapping systems.

About LUMA Vision

LUMA Vision is a privately held medical technology company headquartered in Dublin, Ireland, with key operations in Munich, Germany. The company designs and develops next-generation cardiac visualization and navigation systems that empower clinicians to see and treat with unmatched precision. VERAFEYE™, LUMA Vision’s flagship platform, delivers a real-time, 360° intracardiac view with an unprecedented field of visualization, redefining procedural accuracy in electrophysiology and structural heart interventions. Founded by CEO Fionn Lahart and CTO Christoph Hennersperger, LUMA Vision is committed to transforming cardiac care through innovation that improves outcomes and save lives.

Learn more at www.lumavision.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/luma-vision-to-showcase-verafeye-4d-imaging-platform-at-hrs-2026-signaling-a-new-foundation-for-ep-guidance-302747954.html

SOURCE LUMA Vision

Continue Reading

Technology

Blaize and Datacomm Sign Technology Alliance MOU to Explore AI Inference Solutions Across Indonesia

Published

on

By

Technology Alliance Targets Indonesia’s Growing AI Inference Market, with an Initial Focus on Physical AI, Public Safety, Surveillance, and Industrial AI Applications

EL DORADO HILLS, Calif. and JAKARTA, Indonesia, April 21, 2026 /PRNewswire/ — Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) (“Blaize,” the “Company,” “we,” “our,” or “us”), a global leader in programmable, energy efficient AI computing, and PT Datacomm Diangraha (“Datacomm”), one of Indonesia’s leading IT service providers and cloud infrastructure specialists, today announced the signing of a Memorandum of Understanding (MOU) establishing a technology alliance to explore the potential of AI inference solutions across Indonesia.

The MOU was signed during a ceremony at Gitex Asia 2026 in Singapore, marking a meaningful step in both companies’ shared commitment to advancing practical AI capabilities across the Indonesian market.

Indonesia: A Strategic AI Market

Indonesia is one of the fastest-growing AI markets in Asia Pacific, with global hyperscalers, sovereign infrastructure programs, and enterprise technology providers all accelerating their presence in the country. According to the Empowering Indonesia Report 2025 by Indosat Ooredoo Hutchison and research firm Twimbit, sovereign AI could contribute up to USD $140 billion to Indonesia’s GDP by 2030, driving annual economic growth of up to 6.8%. Indonesia’s AI sector is expanding at a 31% CAGR, the fastest rate in Southeast Asia (Marketing-Interactive, 2026). Blaize and Datacomm are positioning this technology alliance to serve that growing demand, with an initial focus on physical AI, public safety, surveillance, industrial AI, and logistics.

Areas of Exploration

Under the MOU, Blaize and Datacomm intend to explore the following areas of cooperation:

AI Inference as a Service on DCloud: Exploring integration of Blaize’s Hybrid AI platform with Datacomm’s DCloud public cloud platform and datacenter infrastructure to enable scalable inference services for enterprise customers across Indonesia.Physical AI, Public Safety, Surveillance, and Logistics: Exploring AI inference use cases spanning physical security, video analytics, smart surveillance, and logistics optimization across Indonesia’s enterprise and public sector.Industrial AI: Jointly exploring AI inference applications for industrial automation, including computer vision and sensor-driven intelligence for Indonesia’s industrial sector.

“Asia Pacific is at an inflection point for AI inference, and Indonesia stands out as one of the region’s most significant contributors to that growth,” said Dinakar Munagala, Co-Founder and Chief Executive Officer of Blaize. “Datacomm brings exactly the trusted, deeply embedded infrastructure presence and enterprise relationships this market requires. Together, we are exploring how Blaize’s programmable, energy-efficient AI platform can unlock real-world value across public safety, smart infrastructure, physical AI, and logistics throughout Indonesia. This alliance is a strong foundation, and we intend to build on it.”

“At Datacomm, we have spent over three decades earning the trust of Indonesia’s enterprises, government institutions, and critical infrastructure operators,” said Tan Wie Tjin, President Director and Founder of PT Datacomm Diangraha. “Indonesia is on the cusp of a significant AI transformation, and the demand for intelligent, scalable, and secure inference solutions is accelerating across every sector we serve. This alliance with Blaize is a natural and exciting step in our journey toward the AI era. The combination of Datacomm’s cloud and datacenter infrastructure with Blaize’s world-class AI inference platform positions us uniquely to serve this demand. I look forward to exploring the possibilities this technology alliance will unlock for our customers and for Indonesia’s digital future.”

The MOU is non-binding and outlines a cooperative technology framework under which the parties may pursue specific projects through future definitive agreements. The alliance will prioritize enabling secure, scalable, and energy-efficient AI inference solutions that integrate seamlessly into existing cloud, datacenter, and physical environments across Indonesia.

About Blaize

Blaize delivers a programmable AI platform, purpose-built for AI inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP (Graph Streaming Processor), an efficient AI processor, with GPU-based infrastructure, enabling AI inference workloads to run across edge, cloud, and data center. Blaize solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and defense. Blaize is headquartered in El Dorado Hills, California, with a global presence across North America, Europe, the Middle East, and Asia. To learn more, visit www.blaize.com or follow us on LinkedIn @blaizeinc.

About Datacomm

PT Datacomm Diangraha is one of Indonesia’s leading IT service providers, with over 30 years of experience in building and managing critical digital infrastructure. Founded in 1990 and headquartered in South Jakarta, Datacomm has grown from a data communication reseller into a comprehensive technology services company with more than 450 employees. The company serves customers across the enterprise, telecommunications, government, and military sectors through an end-to-end IT ecosystem that supports business transformation, covering cloud services, modern data center solutions, advanced IT security, DevOps, and reliable network infrastructure.

For more information, visit www.datacomm.co.id

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are based on beliefs and assumptions and on information currently available to Blaize, including statements regarding the expected scope of the engagement with Datacomm and any potential definitive agreements related thereto; the industry in which Blaize operates, market opportunities, and product offerings. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) changes in domestic and foreign business, market, financial, political and legal conditions; (ii) failure to realize the anticipated benefits of Blaize’s business combination with BurTech Acquisition Corp., which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; and (iii) those factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 24, 2026, our and other documents filed by Blaize from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Blaize assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law, including the securities laws of the United States and the rules and regulations of the SEC. Blaize does not give any assurance that it will achieve its expectations.

Blaize Contact
press@blaize.com
www.blaize.com 

Investors
ir@blaize.com
www.blaize.com 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/blaize-and-datacomm-sign-technology-alliance-mou-to-explore-ai-inference-solutions-across-indonesia-302748491.html

SOURCE Blaize Inc.

Continue Reading

Trending